DC Chemicals

All products / DC2072

LXR623
CAT. NO. DC2072

LXR623

Pack sizes and prices

Pack sizePrice
100 mg$500 USDRequest a quote →
250 mg$1,000 USDRequest a quote →
1 g$2,000 USDRequest a quote →

In stock. Contact our team for lead time, shipping and final quotation.

Product overview

LXR-623 is a brain-penetrant partial LXRα and full LXRβ agonist, with IC50s of 24 nM and 179 nM, respectively.

For research use only. Results depend on experimental conditions and do not constitute a performance guarantee.

Identity and specifications

Catalog numberDC2072
Product nameLXR623
CAS875787-07-8
Molecular formulaC21H12ClF5N2
Molecular weight422.7784
Purity>98%
SMILESClC1C([H])=C(C([H])=C([H])C=1C([H])([H])N1C(C2C([H])=C([H])C(=C([H])C=2[H])F)=C2C([H])=C([H])C([H])=C(C(F)(F)F)C2=N1)F

Source-listed specifications; the batch COA applies.

Source and product documents

The supplier source is linked below. Contact us for COA, SDS and batch-specific documents.

DC Chemicals — LXR623 (DC2072)

Source references

[1]. Villa GR, et al. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. 2016 Nov 14;30(5):683-693. [2]. Giannarelli C, et al. Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis. Eur Heart J. 2012 Jan;33(2):264-73. [3]. Quinet EM, et al. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res. 2009 Dec;50(12):2358-70. [4]. DiBlasio-Smith EA, et al. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. J Transl Med. 2008 Oct 16;6:59.

Related research products